Neohesperidin dihydrochalcone administration results in significant reduction in activities of two useful markers of liver damage, AST and ALT. The relative levels of NF-κB, IL-6, IL-1β and TNF-α protein in the liver of PQ-treated mice are inhibited by neohesperidin dihydrochalcone. The embryotoxicity/teratogenicity of neohesperidin dihydrochalcone is examined in Wistar Crl:(WI)WU BR rats. No adverse effects are observed at neohesperidin dihydrochalcone levels of up to 5% of the diet, the highest dose level tested, at which the rats consumed about 3.3 g/kg body weight/day.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.